Laboratório Nacional de Computação Científica, Petrópolis, Brazil.
J Mol Graph Model. 2010 Sep;29(2):137-47. doi: 10.1016/j.jmgm.2010.05.007. Epub 2010 Jun 11.
A major concern in the antiretroviral (ARV) treatment of HIV infections with protease inhibitors (PI) is the emergence of resistance, which results from the selection of distinct mutations within the viral protease (PR) gene. Among patients who do not respond to treatment with the PI nelfinavir (NFV), the D30N mutation is often observed. However, several reports have shown that D30N emerges with different frequencies in distinct HIV-1 genetic forms or subtypes. In the present work, we analyzed the binding of NFV and the Gag substrate CA/p2 to PR from HIV-1 subtypes B and C through molecular dynamics (MD) simulations. The wild-type and drug-resistant D30N mutants were investigated in both subtypes. The compensatory mutations N83T and N88D, observed in vitro and in vivo when subtype C acquires D30N, were also studied. D30N appears to facilitate conformational changes in subtype B PR, but not in that from subtype C, and this could be associated with disestablishment of an alpha-helical region of the PR. Furthermore, the total contact areas of NFV or the CA/p2 substrate with the mutant PR correlated with changes in the resistance patterns and replicative capacity. Finally, we observed in our MD simulations that mutant PR proteins show different patterns for hydrophobic/van der Waals contact. These findings suggest that different molecular mechanisms contribute to resistance, and we propose that a single mutation has distinct impacts on different HIV-1 subtypes.
在使用蛋白酶抑制剂 (PI) 治疗 HIV 感染的抗逆转录病毒 (ARV) 治疗中,一个主要关注点是耐药性的出现,这是由于病毒蛋白酶 (PR) 基因内的不同突变的选择导致的。在未对含奈非那韦(NFV)的 PI 治疗产生反应的患者中,经常观察到 D30N 突变。然而,有几项报告表明,D30N 在不同的 HIV-1 遗传形式或亚型中以不同的频率出现。在本工作中,我们通过分子动力学 (MD) 模拟分析了 NFV 和 Gag 底物 CA/p2 与 HIV-1 亚型 B 和 C 的 PR 的结合。研究了两种亚型中的野生型和耐药性 D30N 突变体。还研究了在体外和体内观察到的当 C 型获得 D30N 时出现的补偿性突变 N83T 和 N88D。D30N 似乎促进了 PR 的 B 亚型的构象变化,但不是 C 亚型的构象变化,这可能与 PR 的一个α-螺旋区域的解体有关。此外,NFV 或 CA/p2 底物与突变 PR 的总接触面积与耐药模式和复制能力的变化相关。最后,我们在 MD 模拟中观察到,突变 PR 蛋白显示出不同的疏水性/范德华接触模式。这些发现表明,不同的分子机制导致耐药性,我们提出,单一突变对不同的 HIV-1 亚型有不同的影响。